Flockhart DA - Search Results

1

Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.

Jan MW, ZumBrunnen TL, Kazmi YR, VanDenBerg CM, Desai HD, Weidler DJ, Flockhart DA. Jan MW, et al. Among authors: flockhart da. Drug Metabol Drug Interact. 2002;19(1):1-11. doi: 10.1515/dmdi.2002.19.1.1. Drug Metabol Drug Interact. 2002. PMID: 12222750

2

Discussion: a fresh look at monoamine oxidase inhibitors for depression.

Cohen LJ, Sclar DA, Culpepper L, Flockhart DA, Hirschfeld RM, Thase ME, VanDenBerg CM. Cohen LJ, et al. Among authors: flockhart da. J Clin Psychiatry. 2012;73 Suppl 1:42-5. doi: 10.4088/JCP.11096su1c.07. J Clin Psychiatry. 2012. PMID: 22951242 Free article. No abstract available.

3

Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype.

Marinac JS, Balian JD, Foxworth JW, Willsie SK, Daus JC, Owen R, Flockhart DA. Marinac JS, et al. Among authors: flockhart da. Clin Pharmacol Ther. 1996 Aug;60(2):138-44. doi: 10.1016/S0009-9236(96)90129-0. Clin Pharmacol Ther. 1996. PMID: 8823231

4

CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.

Ramírez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ. Ramírez J, et al. Among authors: flockhart da. Drug Metab Dispos. 2004 Sep;32(9):930-6. Drug Metab Dispos. 2004. PMID: 15319333

5

Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.

Ko JW, Jang IJ, Shin JG, Nam SK, Shin SG, Flockhart DA. Ko JW, et al. Among authors: flockhart da. Clin Pharmacol Ther. 1999 Jun;65(6):606-14. doi: 10.1016/S0009-9236(99)90082-6. Clin Pharmacol Ther. 1999. PMID: 10391666 Clinical Trial.

6

A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.

Williams ML, Bhargava P, Cherrouk I, Marshall JL, Flockhart DA, Wainer IW. Williams ML, et al. Among authors: flockhart da. Br J Clin Pharmacol. 2000 May;49(5):485-8. doi: 10.1046/j.1365-2125.2000.00189.x. Br J Clin Pharmacol. 2000. PMID: 10792207 Free PMC article.

7

Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.

Desta Z, Soukhova NV, Flockhart DA. Desta Z, et al. Among authors: flockhart da. Antimicrob Agents Chemother. 2001 Feb;45(2):382-92. doi: 10.1128/AAC.45.2.382-392.2001. Antimicrob Agents Chemother. 2001. PMID: 11158730 Free PMC article.

8

Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19.

Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Donahue SR, et al. Among authors: flockhart da. Clin Pharmacol Ther. 1997 Nov;62(5):572-7. doi: 10.1016/S0009-9236(97)90054-0. Clin Pharmacol Ther. 1997. PMID: 9390115

9

Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.

Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Xie HG, et al. Among authors: flockhart da. Pharmacogenetics. 1999 Oct;9(5):539-49. Pharmacogenetics. 1999. PMID: 10591534

10

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.

Michaud V, Kreutz Y, Skaar T, Ogburn E, Thong N, Flockhart DA, Desta Z. Michaud V, et al. Among authors: flockhart da. Pharmacogenomics J. 2014 Apr;14(2):151-9. doi: 10.1038/tpj.2013.17. Epub 2013 Apr 30. Pharmacogenomics J. 2014. PMID: 23629159 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

246 results

Search Page

Filters